ARCHIMED to Acquire Esperion Therapeutics in a $1.1 Billion Deal
Esperion Therapeutics, Inc. (ESPR) entered a merger agreement on May 1, 2026, to be acquired by ARCHIMED in a deal valued at $1.1 billion. Deal Structure: Esperion shareholders…
Written byAsif SuriaSource: InsideArbitrage
Esperion Therapeutics, Inc. (ESPR) entered a merger agreement on May 1, 2026, to be acquired by ARCHIMED in a deal valued at $1.1 billion. Deal Structure: Esperion shareholders will receive $3.16 per share in cash at closing, plus one non-tradeable contingent value right (CVR) that will entitle the holder to participate in two contingent milestone